Taiwan equity market Report Interpretation

Overview

This weekly Taiwan market strategy update argues that resilient earnings momentum supports a higher TAIEX target despite modest index gains, foreign technology selling, and sizable ETF outflows. The report combines market performance, positioning, flows, valuation, macro data, and earnings indicators.

Core views

Taiwan equities advanced modestly during the week: TAIEX rose 0.5% and MSCI Taiwan rose 0.6%, outperforming MXAPJ by 0.5 percentage points. Leadership was concentrated in Energy, up 9%, and Banks and Insurance, each up about 7%, while Health Care fell 4%. Technology was broadly flat despite foreign profit-taking, with TSMC down less than 1%; the Taiwan dollar was unchanged at 31.6 per US dollar. The sector pattern showed a rotation toward commodities and financials rather than a broad technology-led move. The central constructive argument is earnings. Consensus 2027E Taiwan EPS rose 0.6%, with positive revisions concentrated in Commodities, Financials, and Transportation and negative revisions in defensives. More broadly, Taiwan earnings have been revised up 4% over one month and 13% over three months. Goldman Sachs' Earnings Revision Leading Indicator suggests that upgrades could accelerate further as economic data remain strong. On this basis, Goldman Sachs raised its 12-month TAIEX target from 51,000 to 54,000, implying 16% upside. Its published top-down EPS growth outlook for Taiwan is 62% for 2026E and 30% for 2027E, compared with consensus forecasts of 65% and 29%, respectively. Reported operating data support the earnings case. Listed-company revenue grew 50% year on year in July, versus 52% in June, and represented 34% of consensus third-quarter estimates against a historical average of 32%. For companies reporting second-quarter 2026 results, net income grew 174% year on year and 34% quarter on quarter; 49% delivered earnings beats versus 37% misses, while median earnings and sales surprises were +14% and +4%. The report treats this evidence as consistent with continued positive earnings revisions rather than as a completed upgrade cycle. Valuation is elevated but incorporated into the target framework: forward 12-month and 24-month P/E were 18.4x and 14.4x, respectively, or 1.4 and 0.5 standard deviations above historical norms. This places greater importance on earnings delivery. The report also records a 12% TSMC ADR premium, up 2 percentage points, while its TSMC ADR Premium Reversal Index stood at 0.0, characterized as relatively stable. Investor flows were mixed. Foreign investors were net sellers of US$2.6bn in cash equities, selling US$0.7bn of TSMC and US$2.4bn of other technology, while buying US$0.8bn of Financials and reducing net short futures positions by US$1.0bn. Domestic funds bought US$130mn, concentrated in technology excluding TSMC, Financials, and Industrials. Retail investors bought US$2.4bn of cash equities, increased margin loans, maintained stable net-long futures positions, and saw short interest decline. In contrast, Taiwan-focused ETFs experienced US$1.8bn of outflows, including US$900mn from active ETFs, US$750mn from broad-market ETFs, and US$350mn from leveraged ETFs; dividend ETFs received US$200mn of inflows. A near-term market-flow catalyst is the FTSE index review effective after the September 18 market close. PharmaEssentia (6446) will replace Alchip (3661) in the FTSE Taiwan 50. Across the Taiwan changes in the FTSE Taiwan, All-World, and All-Cap reviews, Goldman Sachs estimates about US$2.2bn of gross two-way passive flows and US$1.2bn of net passive inflows. The report frames this as a rebalancing-flow event, distinct from the broader earnings thesis. Macro and risk indicators remain relevant to the outlook. The S&P manufacturing PMI was 54.7, down from 55.1 in July. Goldman Sachs expected upcoming inflation to rise 2.2% year on year versus 2.5% previously, and exports to grow 36.0% year on year versus 32.9% previously. Its Cross-Strait Risk Index rose to 79, a reported risk indicator alongside the market and earnings dashboard.

Analysis framework

Goldman Sachs first reviews weekly index and sector performance, then assesses investor positioning and ETF flows. It connects bottom-up consensus EPS revisions, its ERLI model, monthly sales, and reported earnings results to the TAIEX target. It then places the outlook in the context of forward valuation, scheduled FTSE rebalancing flows, macro indicators, and market-risk measures.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Forward 12-month and 24-month P/E valuation

  The report compares Taiwan's forward P/E multiples with historical standard-deviation ranges to contextualize the valuation supporting its index target.

• Quantitative, Factor, and Portfolio Theory

  Earnings Revision Leading Indicator (ERLI)

  Goldman Sachs uses its ERLI model to assess whether consensus earnings upgrades for Taiwan equities are likely to accelerate.

• Event-Driven and Behavioral FinanceEvent-driven analysis

  FTSE index rebalancing flow analysis

  The report estimates passive buying and selling associated with constituent additions, deletions, and index-weight changes effective after September 18.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• TAIEX

  The report-wide market subject; target was raised on stronger earnings expectations.

  Strengths

  Earnings revisions, strong monthly sales, and reported 2Q26 earnings beats support the outlook.

  Weaknesses

  Forward P/E valuations are above historical norms.

  Comparison

  TAIEX outperformed MXAPJ by 0.5 percentage points during the week.

  Risks

  Cross-Strait Risk Index rose to 79; foreign investors were net sellers.

• PharmaEssentia (6446)

  Expected passive-flow beneficiary through addition to the FTSE Taiwan 50.

  Strengths

  Will replace Alchip in the FTSE Taiwan 50.

  Comparison

  Replaces Alchip (3661) in the index review.

  Risks

  Actual rebalancing flows may differ from estimates.

• Alchip (3661)

  Expected passive-flow seller through deletion from the FTSE Taiwan 50.

  Weaknesses

  Will be replaced in the FTSE Taiwan 50.

  Comparison

  Replaced by PharmaEssentia (6446).

  Risks

  Potential passive selling associated with the rebalancing.

Key data

• TAIEX weekly return+0.5%MSCI Taiwan rose 0.6% and outperformed MXAPJ by 0.5 percentage points.
• 12-month TAIEX target54,000Raised from 51,000; implies 16% upside.
• Taiwan earnings revisions+4% over one month; +13% over three monthsERLI indicates upgrades could accelerate further.
• 2027E consensus EPS revision+0.6%Positive revisions were led by Commodities, Financials, and Transportation.
• Forward valuation18.4x f12m P/E; 14.4x f24m P/E1.4 and 0.5 standard deviations above historical norms.
• Foreign cash-equity flow-US$2.6bnSelling was concentrated in TSMC and other technology; Financials received US$0.8bn of net buying.
• Taiwan ETF flows-US$1.8bnOutflows included active, broad-market, and leveraged ETFs; dividend ETFs had US$200mn inflows.
• FTSE rebalancing estimateUS$2.2bn gross two-way flows; US$1.2bn net inflowsEffective after the September 18 market close.
• July listed-company revenue growth+50% year on yearDown from +52% in June and tracking at 34% of consensus Q3 estimates versus a 32% historical average.
• 2Q26 reported earnings+174% year on year; +34% quarter on quarter49% earnings beats versus 37% misses; median earnings and sales surprises were +14% and +4%.

Impact & implications

The report's higher target rests on sustained and potentially accelerating earnings upgrades, while weekly flows show rotation rather than uniformly positive participation. Foreign technology selling and ETF redemptions contrast with domestic and retail buying, and the September FTSE review may temporarily influence individual Taiwan equities through passive flows.

Risks

• Taiwan's Cross-Strait Risk Index rose to 79.
• Elevated forward valuation leaves the market more dependent on earnings delivery.
• Foreign investors were net sellers of Taiwan cash equities, particularly technology.
• Taiwan-focused ETFs recorded US$1.8bn of outflows.

What to watch

• September inflation, for which Goldman Sachs forecast +2.2% year on year versus +2.5% previously.
• September export data, for which Goldman Sachs forecast +36.0% year on year versus +32.9% previously.
• FTSE Taiwan and global index rebalancing effective after the September 18 market close.
• Whether ERLI-indicated earnings upgrades materialize and whether monthly sales continue to support consensus estimates.
• Foreign technology flows, ETF flows, and the Cross-Strait Risk Index.